The most consequential moment in Embody’s enrollment process may come before a clinician decides whether to prescribe. Its website says an OpenLoop Health clinician meets with an individual after checkout to determine prescription eligibility. Meanwhile, the subscription policy makes payments generally nonrefundable, with a narrower exception for medical disqualification. For someone considering the service, understanding when payment, clinical review and pharmacy fulfillment occur is therefore more useful than treating the advertised monthly price as a complete description of care.
Embody, also called JoinEm, presents itself as a GLP-1 weight-management platform operated by Modern Metabolic Medicine, Inc. Its public documentation separates the platform from medical treatment and medication fulfillment: OpenLoop Health provides the clinical services, while independent pharmacies handle prescribed medication. This review follows those handoffs using pages consulted October 19, 2026. It evaluates what the company documents—not independently verified licensing, pharmacy quality or patient outcomes—and highlights the practical questions left unanswered before a patient pays.
At a glance
- Who provides medical care
- Modern Metabolic Medicine, Inc. operates Embody; the site attributes medical treatment to OpenLoop Health, while JoinEm’s terms say the platform does not practice medicine.
- Prescription decision
- The site places the clinician’s prescription-eligibility decision after checkout. Completing the initial assessment does not establish a doctor-patient relationship with Embody.Sources: [8]
- Unreconciled prices
- Homepage injection cards advertise $69/month for GLP-1 and $119/month for GLP-1/GIP, while the terms list different Start and Flat program prices.
- Pharmacy responsibility
- The terms assign fulfillment and shipping to independent pharmacies and carriers not owned, operated or controlled by Modern Metabolic Medicine.Sources: [6]
- Cancellation deadline
- The specific policy requires cancellation requests at least 72 hours before the next billing date; cancellation does not generally refund the purchased term.Sources: [7]
Start with the care team, not the brand name
Embody’s legal operator is Modern Metabolic Medicine, Inc., but the terms explicitly say JoinEm does not provide healthcare services through the platform and is not licensed to practice medicine. The website instead attributes treatment to OpenLoop Health, described as an affiliated network of medical professional corporations and associations. That distinction matters when deciding where to direct a treatment question, request a clinical explanation or clarify responsibility for a prescription.
Access is also narrower than a nationwide website might suggest. The terms require users to be at least 18 and live in the United States in a state or territory where services are available. They say availability is limited to certain states and direct readers to support@joinem.co for the current list. The consulted documentation does not supply that list, full clinical eligibility criteria or systematic laboratory requirements.
Before enrolling, obtain confirmation that care is available where you will receive it and ask which clinical organization will maintain your records. Embody’s privacy notice permits requests for medical and billing records, although access can be limited in specified circumstances and copies may carry a cost-based fee. Our guide to the clinician-platform distinction explains why the company taking payment and the organization delivering care may have different responsibilities.
The assessment is not the prescribing decision
The contact page advertises a two-minute assessment with no card needed to find out whether someone qualifies. That is an initial screening message, not a prescription guarantee: the website separately states that the assessment does not create a doctor-patient relationship with Embody. Its footer places the OpenLoop clinician’s eligibility decision after checkout and reserves the decision to prescribe compounded GLP-1 medication to those clinicians.
The terms describe collecting past and present health conditions, medications, blood pressure, diagnostic tests when applicable, and personal information including location. According to the FAQ, a clinician reviews the completed intake and supporting documentation. If more information is needed before a treatment decision, the service contacts the applicant to schedule a brief virtual appointment. The documentation does not establish that every applicant receives a scheduled live appointment or give a review-time guarantee.
For people transferring from another GLP-1 provider, Embody asks for proof of the current prescription for professional review. That is a documented continuity pathway, not a promise to continue the same prescription unchanged. Before checkout, ask what records are needed, how the consultation will occur and what happens if the review takes longer than expected. Preparing those records in advance is more useful than assuming a short initial assessment means immediate clinical approval.
Resolve the product and price before authorizing payment
The homepage advertises weekly GLP-1 injections at a “flat rate” of $69/month and GLP-1/GIP injections at $119/month. Those cards do not identify the active ingredient, total plan price or commitment needed to obtain the rate. A separate banner advertises $200 off and fast, free shipping without explaining the eligible plan or expiration. The terms describe different prices, so these messages cannot responsibly be combined into one confirmed offer.
The table below preserves the Start program’s introductory and subsequent charges and the Flat semaglutide-injection schedule. Flat also lists adjustments of +$50/month for semaglutide gum, +$100/month for tirzepatide injection and +$50/month for tirzepatide gum. How the gum adjustments apply is not fully explained. Their precise formulation, availability and product-specific safety documentation also remain unconfirmed; an ingredient name alone does not settle those questions.
The FAQ says prices do not increase when doses change within the same medication and lists 4-, 12-, 24- and 52-week plans at checkout. That does not erase Start’s explicit second-month increase, and four weeks is not a calendar month. The terms authorize payment at purchase and recurring charges thereafter. They do not clearly establish the collection schedule or final checkout total for every bundle; request both rather than inferring mandatory full prepayment from package duration.
| Program and product | Initial or monthly price | Later charge or commitment detail |
|---|---|---|
| Start: semaglutide injection | $99 first month | $299/month from month two |
| Start: semaglutide gum | $149 first month | $349/month from month two |
| Start: tirzepatide injection | $149 first month | $399/month from month two |
| Start: tirzepatide gum | $199 first month | $449/month from month two |
| Flat: semaglutide injection | $199/month monthly; $169/month for three months | $159/month for six months; $149/month for twelve months; bundle collection schedule unclear |
What the subscription includes—and what stays conditional
The homepage says medication is included in the Embody Program. The subscription policy gives the more qualified description: the bundled price includes access to healthcare providers, medication when clinically appropriate, laboratory services when applicable, online support and related services. It is not itemized by individual service, visit, shipment or month, and the policy says no portion is separately refundable. Paying for the program therefore does not guarantee a particular prescription or laboratory service.
Embody also advertises free, optional care coaching for education, motivation and accountability. The site explicitly says coaches are not clinicians and participation is not required to receive medication. Separately, it promotes 24/7 access to specialists, unlimited appointments and messaging as often as needed. Those are provider service claims; the consulted pages do not define a mandatory clinical follow-up schedule or a guaranteed clinician response time.
The website’s “no insurance barriers” message describes direct access without insurance approvals, denials or delays. It does not establish that Embody bills an insurer, that medication is covered or that reimbursement is available. HSA/FSA terms are also unconfirmed. A useful prepayment question is therefore not simply whether everything is included, but which services are conditional, who decides when they are needed and how access works during the purchased term.
The prescription passes to an independent pharmacy
After treatment approval, the FAQ says the prescription goes to a pharmacy for fulfillment and shipment to the address on file. The terms clarify that independent third-party pharmacies and delivery carriers—not businesses owned, operated or controlled by Modern Metabolic Medicine—perform those functions. The website names Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx as partners, but does not identify which one would fill an individual patient’s prescription.
Embody describes compounded medications as customized prescriptions prepared by state-licensed 503A compounding pharmacies and says its partners follow quality standards and conduct extensive testing. Those are provider representations, not independently verified findings from this review. The consulted pages do not provide patient-specific pharmacy assignments or batch-testing results. Before fulfillment, ask for the dispensing pharmacy’s identity, the exact product and presentation, and the contact route for questions about preparation or instructions.
FDA guidance supplies an important boundary: compounded preparations are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality. FDA recommends them when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence. Our pharmacy-handoff questions can help distinguish the prescriber’s responsibilities from the pharmacy’s without treating either as interchangeable with the platform.
Delivery has no documented arrival clock
Embody advertises free expedited home delivery, but the consulted documentation supplies no numerical arrival promise. It also does not establish separate timelines for clinical review, pharmacy preparation, dispatch or transit, identify the carrier, or describe shipment frequency and cold-chain arrangements. Approval is not dispatch, and dispatch is not arrival. A plan lasting several months likewise does not establish how much medicine arrives in one shipment or how often packages follow.
The delivery policy distinguishes damaged and incorrect items. Damaged items may be replaced by the pharmacy after evidence of damage is received; incorrect items will be replaced. In both cases, the policy identifies replacement—not a refund—as the remedy. Ask how to document a problem, whom to notify and whether replacement timing is tracked separately from the ordinary fulfillment process. The public terms do not answer all of those operational questions.
For temperature problems, FDA’s advice is explicit: do not use an injectable GLP-1 medicine that arrives warm or with insufficient refrigeration, and contact the provider or dispensing pharmacy. That guidance is separate from Embody’s commercial replacement policy. Our guide to warm injectable deliveries explains the distinction. Free shipping is a delivery-price claim, not proof of adequate temperature control or a guarantee that a replacement will arrive by a particular date.
Follow-up needs a clinical channel, not just customer support
The contact page publishes support@joinem.co and (347) 269-4270 and says the care team is available 24/7. For questions about a patient’s own treatment, however, it directs the patient to the portal so the message reaches the clinician directly. That is a useful routing distinction: payment or account questions have a public support route, while treatment questions have a designated clinical route. Around-the-clock support does not establish an immediate clinical answer.
The documentation does not specify a required follow-up interval, monitoring schedule or response-time standard. Ask how follow-up is arranged, whether check-ins are scheduled or patient-initiated, and how concerns reach the prescribing clinician between appointments. NIDDK describes medication selection as a discussion of benefits, side effects, health conditions, other medicines, family history and costs. It also emphasizes that follow-up concerns response and tolerability, rather than simply continued payments or prescription renewal.
Embody’s safety index includes compounded semaglutide and tirzepatide injections, plus information on Ozempic, Mounjaro and Rybelsus. An entry in that index is not confirmation that the named product is sold or included in a plan. The site also attributes benefit claims to customer self-reports involving compounded GLP-1 treatment and consultations. Those reports are not independently measured provider outcomes, and product safety information should not be mistaken for evidence that this particular care pathway produces advertised results.
Leaving the program follows billing rules, not just shipment status
The homepage says patients can cancel before their next medication shipment to avoid the upcoming cycle, with cancellation deferred if the shipment has already been processed. The specific cancellation policy instead requires a request at least 72 hours before the next billing date. Requests inside that window leave the current charge payable and nonrefundable, with cancellation effective the following cycle. These are different clocks; obtain the actual renewal date and written confirmation rather than relying on shipment status.
Cancellation is available through support email, telephone or the online account/patient portal. It generally stops future renewal rather than unwinding a purchase. The policy makes single-month, multi-month and bundled payments final and nonrefundable at purchase, even if services go unused. Failure to finish intake, attend a consultation or accept a prescription does not create refund entitlement. Multi-month bundles exchange a discounted rate for a full-term commitment, without refunds or credits for unused services or unshipped medication.
Medical disqualification is the stated exception, but it is not an unconditional full refund. The policy refunds the unused portion of the current term after accounting for services already considered used, including clinical review, consultations, issued prescriptions, dispensed or shipped medication and ordered or performed laboratory services. Those deductions are not quantified in the consulted pages. Before choosing a longer package, use these questions about changing a program to clarify both cancellation timing and the financial consequences of leaving.
Questions & answers
Can I learn whether I qualify before entering a card?
Embody advertises a two-minute initial assessment with no card needed. However, that assessment does not create a doctor-patient relationship with Embody, and the site places the clinician’s prescription-eligibility decision after checkout. Treat initial screening and clinical approval as separate steps, and ask what financial terms apply between them before paying.
Will Embody continue a prescription from my current provider?
The site welcomes people already taking GLP-1 medication and requests proof of their current prescription for professional review. That confirms a transfer-review process, not guaranteed continuation. Ask what supporting records are necessary and when review can occur; the consulted pages do not promise a transfer turnaround or uninterrupted medication availability.
Is $69 a confirmed price for any semaglutide injection plan?
No such match is established by the consulted documentation. The homepage’s $69/month GLP-1 injection card does not name the ingredient or commitment, while the terms list other semaglutide injection prices. Request the exact product, introductory and renewal charges, total commitment and payment schedule shown for your selected checkout offer.
Who should receive a question about my treatment?
Embody directs personal treatment questions through the patient portal so they reach the clinician. Public support is available at support@joinem.co or (347) 269-4270 for account and service contact. The advertised 24/7 availability does not supply a guaranteed clinician response time, so clarify how clinical messages are handled before relying on that wording.
Can I choose which partner pharmacy fills my prescription?
The website lists four pharmacy partners, but the consulted pages do not establish a patient-choice policy or identify the pharmacy assigned to each prescription. Ask before fulfillment which pharmacy will dispense the medication and how to contact it. The terms place fulfillment and shipping with independent pharmacies and carriers rather than the platform operator.
If a clinician finds me ineligible, will all my money come back?
Not necessarily. The medical-disqualification exception provides a refund for the unused portion of the current term, with deductions for services considered used. Clinical review itself can count, as can consultations, issued prescriptions, medication fulfillment and laboratory services. The documentation does not quantify those deductions, so ask how the calculation would work for your selected program.
Our assessment
Embody documents a recognizable care pathway: initial screening, post-checkout clinician review, independent pharmacy fulfillment and portal-based treatment communication. Naming the clinical network, pharmacy partners and support channels helps make those handoffs visible. Its optional nonclinical coaching is also clearly distinguished from medical care. The unresolved issues are consequential, however: advertised prices do not reconcile with the program tables, clinical and delivery timelines are unspecified, and shipment-based cancellation language differs from the policy’s 72-hour billing deadline. Longer packages carry explicit full-term financial commitments, while medical-disqualification refunds may be partial. Before paying, obtain written confirmation of the exact product, assigned clinical and pharmacy contacts, checkout total, collection schedule, follow-up process and cancellation date. The documentation supports evaluating Embody as a GLP-1 platform, but not assuming that its marketing alone defines the care or financial terms an individual will receive.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Embody (joinem.co; también denominado JoinEm) — pages/privacy practices ↗
- Embody (joinem.co; también denominado JoinEm) — pages/contact ↗
- Embody (joinem.co; también denominado JoinEm) — pages/glp1_medication_safety_information ↗
- Embody (joinem.co; también denominado JoinEm) — pages/terms conditions ↗
- Embody (joinem.co; también denominado JoinEm) — pages/refund policy ↗
- Embody (joinem.co; también denominado JoinEm) — official website ↗